Safety evaluation of beta-nicotinamide mononucleotide oral administration in healthy adult men and women.

This human trial addressed a gap in the NMN literature: whether repeated daily oral doses at or above 1000 mg are safe in healthy adult men and women, which earlier clinical work had not reported. Participants took oral NMN and were monitored on standard safety measures. It extends the oral NMN safety record to higher repeated daily doses. This is human safety evidence and is not a study of clinical outcomes.

For your business

Daily oral NMN at doses ≥1000 mg appears well-tolerated in healthy adults, supporting confidence when discussing higher-dose supplementation.

Read more on Scientific reports →

Shopping Cart
Scroll to Top